Amgen and Novartis Shares Slump Following Disappointing Phase-3 Trial Results

Key Facts

1Amgen shares sold off after Novartis failed to meet its primary endpoint in phase-3 clinical trials.

In a move reflecting the healthcare sector's high sensitivity to research and development outcomes, Amgen shares experienced a sell-off according to reports. This downward price action followed the announcement that Novartis failed to meet the primary endpoints in its phase-3 clinical trials. Such failures in late-stage trials are critical factors that directly impact investor confidence in the future drug pipelines of mega-cap pharmaceutical firms.

The selling pressure extended to both Novartis (NVSEF) and Amgen (AMGN) shares, as the trial disappointment triggered volatility across related healthcare stocks. Per market dynamics, clinical trial failures for major pharma companies typically lead to immediate share price corrections due to the high costs associated with these research programs. Markets are currently monitoring how these results will influence broader sector valuations amid an economic environment focused on capital expenditure efficiency.

Regarding current price levels, specific closing data for September 8, 2026, is unavailable, necessitating a focus on qualitative price trends in upcoming sessions. Within the economic calendar, there are no immediate upcoming catalysts specifically for the healthcare sector; however, investors will be watching for further corporate statements regarding the implications of these trial results on future strategic goals.